Losartan

• Description:

  Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.

• Product Name Alternative:

  DuP-753

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Angiotensin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease; Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Losartan.html

• Purity:

  99.57

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2

• Molecular Formula:

  C22H23ClN6O

• Molecular Weight:

  422.91

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103 (6) : p. 904-12.|[2]Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014.|[3]Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126 (1) : p. 124-31.|[4]Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312 (5770) : p. 117-21.|[5]Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26 (2) : p. 233-40.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  AT1 Receptor

• Citation 01:

  Adv Healthc Mater. 2025 Apr;14 (11) :e2500176.|Adv Sci (Weinh) . 2024 Dec 5:e2410360.|Am J Physiol Heart Circ Physiol. 2018 Mar 1;314 (3) :H580-H592.|Am J Physiol Renal Physiol. 2020 Nov 1;319 (5) :F941-F953.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|Antioxidants (Basel) . 2024 Aug 7;13 (8) :958.|Apoptosis. 2024 Oct;29 (9-10) :1499-1514.|Arch Biol Sci. 2021 Jun.|Biochem Biophys Res Commun. 2025 Jan:745:151256.|Biomolecules. 2022 Nov 25;12 (12) :1754.|Biomolecules. 2023 Apr 25;13 (5) :740.|Cell Mol Life Sci. 2025 Nov 13;82 (1) :396.|Clin Sci. 2021 Mar 26;135 (6) :793-810.|Clin Transl Med. 2023 Mar;13 (3) :e1213.|Clin Transl Med. 2025 Jun;15 (6) :e70361.|Eur J Pharmacol. 2025 Dec 15:1009:178390.|FASEB J. 2018 Sep;32 (9) :5051-5062.|FASEB J. 2025 Jul 15;39 (13) :e70761.|Friedrich-Alexander University Erlangen-Nuremberg. 2023 May 2.|Front Physiol. 2020 Sep 8;11:560170.|Gene. 2022 Apr 30:820:146239.|Int Immunopharmacol. 2023 Oct:123:110761.|Int Immunopharmacol. 2024 Jul 19:139:112707.|Int Immunopharmacol. 2025 Sep 23:162:115168.|Int J Mol Sci. 2023 Feb 3;24 (3) :2960.|Int J Nanomedicine. 2018 Nov 13:13:7409-7426.|J Immunother Cancer. 2024 Sep 6;12 (9) :e009327.|J Mol Cell Cardiol. 2025 May:202:133-143.|J Orthop Surg Res. 2024 Feb 19;19 (1) :147.|J Pharmacol Sci. 2020 Sep;144 (1) :30-42.|J Physiol. 2024 Jan;602 (2) :317-332.|J Transl Med. 2024 Jan 5;22 (1) :26.|Mol Biomed. 2025 Feb 11;6 (1) :10.|Nefrologia. 2023 Sep 6.|Oncogene. 2023 Apr;42 (15) :1166-1180.|Oxid Med Cell Longev. 2022 Feb 18;2022:5044046.|Phytomedicine. 2022 Mar 21;100:154067.|Phytomedicine. 2023 Apr:112:154700.|Rep Biochem Mol Biol. 2021 Jul;10 (2) :314-326.|Res Sq. 2024 Jul 16.|Research Square Print. September 13th, 2022.|Sci Rep. 2019 Dec 19;9 (1) :19450.|SSRN. 2025 Nov 6.|Toxicol Appl Pharmacol. 2024 May:486:116945.|Toxicol Lett. 2025 Apr:406:31-37.|Cell Death Dis. 2020 May 22;11 (5) :390.|Chem Biol Interact. 2023 Sep 1:382:110636.|Colloids Surf B Biointerfaces. 2025 Nov 25:259:115314.|FASEB J. 2019 May;33 (5) :6254-6268. |Nat Commun. 2025 Nov 25;16 (1) :10430.|Phytomedicine. 2024 Dec 3:136:156314.

• CAS Number:

  [114798-26-4]